In clinical trials, managing risks that could impact data quality is crucial for ensuring patient safety, data integrity, and regulatory compliance. While Risk-Based Quality Management (RBQM) and Quality Risk Management (QRM) are both approaches designed to manage risks, the two have essential differences.
Cyntegrity's latest version of the MyRBQM® Portal, V7.3.1, brings several improvements to enhance your user experience. With a focus on data security, the release includes security updates that predict and prepare for potential breaches.
You won't want to miss our latest press release announcing the cooperation between Cyntegrity and PwC! The collaboration brings together Cyntegrity's cutting-edge technology solutions with PwC's expertise in professional services, data integration, and M&A activities.
We're thrilled to announce that we've passed our SOC 2 Type 2 examination, which confirms our effective controls over confidentiality, privacy, and processing of online cloud platforms. SOC 2 compliance demonstrates our high level of information security and responsible handling of sensitive information.
Looking for a comprehensive RBQM software solution for your clinical trials? Look no further than Cyntegrity, your premier RBQM software vendor. Our suite of RBQM tools is designed to help you proactively manage risk, enhance data privacy and security, and improve the quality and efficiency of your clinical trials. With our user-friendly tools, real-time monitoring and reporting, and dedicated customer support, Cyntegrity is the ultimate choice for all your RBQM software needs. And with the Cyntegrity MyRBQM Academy, you can enhance your RBQM expertise and take your clinical trials to the next level. Choose Cyntegrity as your premier RBQM software provider and transform your clinical trials today.
Exciting news on ICH GCP E6(R3) is here! Our CEO, Artem Andrianov, returned from the SCOPE Summit with updates on the updated guideline. ICH E6(R3) will incorporate technology advancements while prioritizing participant protection and reliable evidence. Don't miss Artem's thoughts on his experience at the summit. Stay tuned for more updates on ICH E6(R3)!
In an interview with Applied Clinical Trials, CEO Artem Andrianov discusses the inspiration behind the tool, its benefits to the industry, and its functionality. The tool is aimed to improve patient outcomes by reducing the risk of negative reactions to combined medications.
We are proud to announce that our Drug Interaction Visualizer has been selected as a finalist for the SCOPE Best of Show Awards. Based on real-world data from the FDA, our visualizer enables clinical research professionals to explore drug interactions and identify potential risks.
The eyesON Drug-Drug Interaction visualizer provides unique profiles of the most common adverse events and side effects of the market's most frequently prescribed and used FDA-regulated drugs.
Learn about the high failure rate of clinical trials & how the premortem approach can improve success by identifying potential problems early. Discover how this technique can foster a culture of collaboration & learning within the team, reducing the need for a painful postmortem.
